360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Actelion Pharmaceuticals Ltd

Type: Company

Name: Actelion Pharmaceuticals Ltd (Actelion Ltd)

Nationality: Switzerland

Web Address: http://www.actelion.com/

Fact Sheet: Fact Sheet for Actelion Ltd

First reported May 21 2013 - Updated May 22 2013 - 1 reports

Bayer bolsters campaign for PAH drug riociguat with positive long-term data

Bayer has a new set of upbeat results from its long-term extension study of riociguat, a major new player in a busy field of competitors angling for a share of the market for pulmonary arterial hypertension.Investigators say they tracked further improvements ... [Published FierceBiotech - May 21 2013]

Entities: Pulmonary Arterial Hypertension, Bayer AG, Drugs, Patient, Actelion Pharmaceuticals Ltd

First reported May 20 2013 - Updated May 21 2013 - 1 reports

Bayer AG

Bayer says lung drug shows promise in prolonged trial

Bayer said extendeduse of its experimental riociguat pill to treat alife-threatening form of high blood pressure in the lungs wasshown to be safe and effective in a prolonged trial.In the extension of a late-stage trial, the drug was shown to help people ... [Published Reuters - May 20 2013]

Entities: Bayer AG, Pulmonary Arterial Hypertension, Drugs

First reported May 20 2013 - Updated May 20 2013 - 1 reports

How to Commercialize Narrow-Indication Products

The eroding blockbuster model has forced the pharmaceutical industry to diversify its go-to-market approach. Narrow-indication products are becoming a more popular option for Big Pharma, but what is the optimal way to bring such products to market? ... [Published Pharma-Mag - May 20 2013]

Entities: Big Pharma, Economic Potential, Drugs, best practice, Paul Gardiner

First reported May 17 2013 - Updated May 17 2013 - 10 reports

Additional macitentan (Opsumit) data in pulmonary arterial hypertension presente..

Actelion Pharmaceuticals Ltd / Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. ALLSCHWIL/BASEL, ... [Published Saudi Fransi Capital - May 17 2013]

Entities: Pulmonary Arterial Hypertension, Macitentan, Actelion Pharmaceuticals Ltd, Opsumit, endothelin receptor antagonist

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Transocean Ltd

Swiss Stocks Are Little Changed as Actelion, Transocean Advance

May 14 (Bloomberg) -- Swiss stocks were little changed before reports on German investor confidence and euro-area industrial production.Actelion Ltd. and Transocean Ltd. posted the biggest gains on the Swiss Market Index. ABB Ltd. led falling stocks.The ... [Published La Repubblica - May 14 2013]

Entities: Actelion Pharmaceuticals Ltd, Transocean Ltd, Stocks, Index

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Actelion Pharmaceuticals Ltd

7.00% p.a. CHF Kick-In GOAL auf Actelion / Galenica / Roche (KIBXQ)

Offizielle Mitteilung Nr: 91287 Titel: ISIN: CH0206482264 Das oben aufgeführte Produkt wird infolge des Erreichens des Strike Levels am 13. Mai 2013 vom Handel an der SIX Swiss Exchange genommen und zu den folgenden Bedingungen zurückbezahlt: Rückzahlungsbetrag: ... [Published SIX Swiss Exchange - May 14 2013]

Entities: Galenica AG, Actelion Pharmaceuticals Ltd, SIX Swiss Exchange

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Holcim Ltd

The Swiss Stock Market Closed Above 8,000 For The First Time In Over 5 Years

BRUSSELS (dpa-AFX) - The Swiss stock market surged to the upside Wednesday, adding to gains from the gains of the previous session. The market received a boost from the positive performance in Asia and the U.S., as well as some better than expected economic ... [Published FinanzNachrichten.de - May 08 2013]

Entities: Stock Market, Actelion Pharmaceuticals Ltd, Holcim Ltd

First reported May 08 2013 - Updated May 08 2013 - 4 reports

UPDATE 1-Actelion gets go-ahead to continue new drug trial

* Selexipag is new drug for pulmonary arterial hypertension* Final results due by mid 2014* Actelion looking for alternatives to main drug Tracleer (Adds details, background)ZURICH, May 8 (Reuters) - Actelion should continue a late-stage study into a ... [Published Reuters - May 08 2013]

Entities: Actelion Pharmaceuticals Ltd, Pulmonary Arterial Hypertension, Drugs

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Swiss Stocks Advance, Extending Five-Year High, as Holcim Climbs

May 8 (Bloomberg) -- Stocks in Switzerland rose, extending the benchmark Swiss Market Index’s highest level in more than five years, as Chinese imports and exports increased more than forecast and Holcim Ltd. climbed after releasing earnings.Holcim, the ... [Published La Repubblica - May 08 2013]

Entities: Holcim Ltd, Stocks, Switzerland, Actelion Pharmaceuticals Ltd

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Actelion gets go-ahead to continue new drug trial

Factors to watch on April 16 Actelion said in a statement the Independent Data Monitoring Committee had told the company it had unanimously recommended the continuation of a late-stage study in selexipag with no modifications, adding final results should ... [Published Reuters - May 08 2013]

Entities: Actelion Pharmaceuticals Ltd, Drugs

First reported May 07 2013 - Updated May 07 2013 - 1 reports

BLOGSCAN - An Ex-Pharmaceutical Company CEO to Run the American College of Cardiology?

Marilyn Mann's blog discussed the appointment of a former pharmaceutical company executive, most recently at Actelion, and previously at Hoffman La Roche, Abbott Canada, Nordic Labs and Marion Merrill Dow (now known as Aventis), as president of the ... [Published Health Care Renewal - May 07 2013]

Entities: Actelion Pharmaceuticals Ltd, American College of Cardiology, Drugs, Generic Drug, Patient

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Most Stocks in Switzerland Decline as Actelion Falls

Most Swiss stocks dropped, after the Swiss Market Index last week rallied to its highest level in five years, before a report that may show euro-area retail sales declined for a second month in March.Actelion Ltd. (ATLN) led losses on the benchmark g ... [Published Bloomberg - May 06 2013]

Entities: Actelion Pharmaceuticals Ltd, Switzerland, Pierre Moscovici, Stocks

Quotes

Humbert M, et al "Efficacy of riociguat in pretreated versus treatment-naïve patients with pulmonary arterial hypertension (PAH) in the phase IIIIII PATENT-1 study" Am J Respir Crit Care Med 2013: A3534

Riociguat Shows Promise in Pulmonary HTN [Published MedPage Today - May 23 2013]

"Despite the availability and advantages of several approved PAH therapies, the prognosis for patients remains poor and mortality remains high. The interim results of PATENT-2 support the benefits of riociguat that were seen in the PATENT-1 trial. We are confident that, together, these results reinforce the role of riociguat, if approved, as a new treatment in the armamentarium against PAH" said Kemal Malik, head of global development at Bayer

Bayer bolsters campaign for PAH drug riociguat with positive long-term data [Published FierceBiotech - May 21 2013]

As a supplement to the ATS conference Actelion will host a symposium with Richard Channick, MD. The program entitled: "Emerging Developments and Insights in Pulmonary Arterial Hypertension: How We Think, How We Practice." will be hosted at Millennium Hall, Loews Philadelphia Hotel on Tuesday 21 May between 18:30 and 21:00

Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS (Actelio ... [Published Presscontacts.com - May 17 2013]

"We are very pleased to have completed enrollment in our Phase II trials in canine and human lipoma and we remain on track to report top-line data for both trials in the second half of this year" reflected Thomas L Wegman, President of BioSpecifics. $ First Quarter 2013 Financial Results

BioSpecifics Technologies Corp. Reports First Quarter 2013 Financial Results PR Newswire [Published Yahoo! Finance - May 10 2013]

More Content

sort by: Date \| Relevance
Positive Data on Bayer Candidate [Published Yahoo! Finance - 10 hours ago]
Riociguat Shows Promise in Pulmonary HTN [Published MedPage Today - May 23 2013]
Bayer bolsters campaign for PAH drug riociguat ... [Published FierceBiotech - May 21 2013]
Control of Myeloid Cell Trafficking in Resolution [Published Sexual Development - May 21 2013]
Bayer says lung drug shows promise in prolonged... [Published Reuters - May 20 2013]
How to Commercialize Narrow-Indication Products [Published Pharma-Mag - May 20 2013]
Additional macitentan (Opsumit) data in pulmona... [Published Saudi Fransi Capital - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published Presscontacts.com - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published Yahoo! Finance - May 17 2013]
Actelion Pharmaceuticals Ltd : Additional macit... [Published Investegate - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published Best Invest - May 17 2013]
ACTELION LTD : Additional macitentan (Opsumit) ... [Published 4 Traders - May 17 2013]
Actelion Pharmaceuticals Ltd: Additional macite... [Published FinanzNachrichten.de - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published Reuters - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published ACN Newswire - May 17 2013]
Additional macitentan (Opsumit) data in pulmona... [Published TD Ameritrade - May 17 2013]
Lundbeck's Steve Turley re-elected as EMG chair [Published PMLive - May 16 2013]
7.00% p.a. CHF Kick-In GOAL auf Actelion / Gale... [Published SIX Swiss Exchange - May 14 2013]
Swiss Stocks Are Little Changed as Actelion, Tr... [Published La Repubblica - May 14 2013]
Drug Patent Expirations for May 13 2013 [Published Biotech Blog - May 13 2013]
Brand, Generic Disputes Over Access Move Beyond... [Published The Rose Sheet - May 13 2013]
Drug Patent Expirations in May 2013 [Published Biotech Blog - May 13 2013]
BioSpecifics Technologies' Management Discusses... [Published Seeking Alpha - May 10 2013]
Bacterial Partnering Terms and Agreements - 201... [Published PredictWallStreet - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published Yahoo! Finance - May 10 2013]
BioSpecifics Technologies Corp. Reports First Q... [Published Staten Island Live - May 10 2013]
Viral Partnering Terms and Agreements - 2013 Re... [Published Individual.com - May 09 2013]
Which Big Biotechs are hitting the gas pedal on... [Published FierceBiotech - May 08 2013]
The Swiss Stock Market Closed Above 8,000 For T... [Published FinanzNachrichten.de - May 08 2013]
The Swiss Stock Market Closed Above 8,000 For T... [Published RTTNews.com - May 08 2013]

Blogs

sort by: Date \| Relevance
How to Commercialize Narrow-Indication Products [Published Pharma-Mag - May 20 2013] The eroding blockbuster model has forced the pharmaceutical industry to diversify its go-to-market approach. Narrow-indication products are becoming a more popular option for Big Pharma, but what is the optimal way to bring such products to market? ...
Drug Patent Expirations for May 13 2013 [Published Biotech Blog - May 13 2013] Copyright © thinkBiotech If your reader cannot render the information below, go tohttp://www.DrugPatentWatch.com/innovation to see the latest expirationsbody { font-family:Calibri, tahoma, arial,sans-serif;}table { font-size:12px; font-family:Calibri, ...
Drug Patent Expirations in May 2013 [Published Biotech Blog - May 13 2013] Copyright © thinkBiotech Drug Patent Expirations for May 2013TradenameApplicantGeneric NamePatent NumberPatent Expiration HUMALOG PEN Lilly insulin lispro recombinant 5,514,646 May 7, 2013 GEMZAR Lilly gemcitabine hydrochloride 5,464,826*PED ...
BLOGSCAN - An Ex-Pharmaceutical Company CEO to ... [Published Health Care Renewal - May 07 2013] Marilyn Mann's blog discussed the appointment of a former pharmaceutical company executive, most recently at Actelion, and previously at Hoffman La Roche, Abbott Canada, Nordic Labs and Marion Merrill Dow (now known as Aventis), as president of the ...
Actelion Ltd. Earnings Call Insights: Domestic ... [Published Wall St. Cheat Sheet - Apr 17 2013] Actelion Ltd. ( NASDAQ:ATLN ) recently reported its first quarter earnings and discussed the following topics in its earnings conference call.Domestic InventoryRavi Mehrotra – Credit Suisse : Congratulation on a great quarter. Let me ask the most obvious ...

Press Releases

sort by: Date \| Relevance
Research and Markets: Actelion Partnering 2005-... [Published Business Wire Health News - May 07 2013]
Actelion Pharmaceuticals Rusia implementa Cloud... [Published Business Wire Technology News - Apr 29 2013]
Actelion Pharmaceuticals Rusia implementa Cloud... [Published Business Wire Health News - Apr 29 2013]
Research and Markets: Idiopathic Pulmonary Fibr... [Published Business Wire - Apr 16 2013]
Samenvatting: Actelion Pharmaceuticals Russia h... [Published Business Wire Technology News - Apr 12 2013]